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Abstract
After more than 40 years of use, Praziquantel (PZQ) still remains the drug of choice for the
treatment of intestinal and urogenital schistosomiasis. Its anti-parasitic activity resides pri-
marily in the (R)-enantiomer. Hitherto neither the molecular target nor the pharmacokinetic-
pharmacodynamic relationship have been fully elucidated. Here we investigated the efficacy
and pharmacokinetics of PZQ in the Schistosoma mansoni mouse model to determine the
key factors that drive its efficacy. Dose-response studies with racemic PZQ with or without
addition of an irreversible pan-cytochrome P450 (CYP) inhibitor, 1-aminobenzotriazole
(ABT), were performed. In addition, efficacy of PZQ in the presence of the CYP inducer,
dexamethasone (DEX), was determined. Plasma samples were obtained by tail vein bleed-
ing at 4 time points. The (R)-PZQ levels were determined using a LC-MS/MS method. Non-
compartmental pharmacokinetic analysis was performed using PKsolver. In addition, exper-
iments using an enhanced in vitro assay were conducted. We found that the use of ABT
increased (R)-PZQ plasma exposures in the systemic circulation by ~10 to 20 fold but the
latter were not predictive of efficacy. The use of DEX decreased plasma exposures of (R)-
PZQ in the systemic circulation by ~10 fold without reducing efficacy. We extrapolated the
(R)-PZQ concentrations in mouse portal vein / mesenteric veins from the systemic expo-
sures and found that a free exposure of (R)-PZQ of ~ 20 μM*h in the portal vein was needed
to obtain a worm burden reduction >60%. It is suggested that the high (R)-PZQ concentra-
tions available before the hepatic first pass metabolism drive the efficacy against S. mansoni
adult worms residing in the mesenteric veins. It is then possible that the current dosing regi-
men of 40 mg/kg in preventive chemotherapy programs may provide suboptimal concentra-
tions in low-weight patients such as children, due to smaller total amounts of drug
administered, and may consequently result in lower cure rates.
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Author summary
After more than 40 years of use, Praziquantel (PZQ) still remains the drug of choice for
the treatment of intestinal and urogenital schistosomiasis. However the relationship
between pharmacokinetics and efficacy is not elucidated. For adults infected with intesti-
nal schistosomiasis, a single oral dose of PZQ at 40 mg/kg is generally recommended by
the World Health Organisation for preventive chemotherapy programs. By reducing
hepatic metabolism with a pan-CYP inhibitor, we studied the systemic plasma exposure
relationship versus activity in the Schistosoma mansoni mouse model. For S. mansoni
infections where the worms are located in the mesenteric veins, we found that systemic
plasma exposure was not predictive of efficacy, whereas estimated portal vein concentra-
tion of PZQ acts as a good predictor for the efficacy. This hypothesis was confirmed by
pre-treatment of mice with a CYP inducer which led to a ~10 fold decrease in systemic
plasma exposure while maintaining the efficacy of PZQ. This implies that the critical
parameters are the rate and amount of PZQ absorbed, in order to achieve the required
high local concentrations in the mesenteric veins. Therefore in pediatric patients the cur-
rent dosing regimen of 40 mg/kg may provide suboptimal concentrations and conse-
quently result in lower cure rates in S. mansoni infections.
Introduction
Schistosomiasis [1–3] causes significant morbidity and mortality in subtropical and tropical
regions of the world and estimates show that at least 258 million people required preventive
treatment for schistosomiasis in 2014 [4]. Today treatment and control relies essentially on
Praziquantel and gaps in the access plan to pre-school aged children remain an important
issue along with an adequate pediatric formulation [5].
PZQ (1975) is administered as a racemate with the (R)-enantiomer (also described as
L-PZQ) primarily accounting for the anti-parasitic activity [6]. PZQ has shown activity against
all Schistosoma species but on adult worms only [7,8]. However after more than 40 years of
use, neither the molecular target nor the pharmacokinetic-pharmacodynamic (PK/PD) rela-
tionship have been elucidated [9,10]. These lacking data hamper progression of much needed
new chemical entities and may also raise questions regarding the suboptimal response of PZQ
observed in some published pediatric studies [11,12]. To investigate the efficacy and pharma-
cokinetics of PZQ in a preclinical setting, the well-established Schistosoma mansoni mouse
model is probably the most suited as it uses the most predominant species infecting humans
with intestinal schistosomiasis and resides also in the same target organ, i.e. the mesenteric
veins [13]. Besides obvious anatomical differences, two notable discrepancies are of course the
immunity and the clearance which is greater in mice, although metabolic pathways are similar,
mediated by cytochrome P450 (CYP) enzymes [14]. To circumvent rapid phase I metabolism,
mice can be treated with 1-aminobenzotriazole (ABT), an irreversible pan-CYP inhibitor, with
the intent to increase the systemic plasma exposure and enable to draw correlations between
systemic exposure and efficacy [15]. Then additional insights may be obtained by the route of
administration of ABT: an oral (p.o.) administration of ABT will reduce the intestinal and
hepatic CYP-mediated metabolism whereas intravenous (i.v.) administration of ABT should
predominantly reduce liver metabolism. After p.o. administration and before hepatic first pass,
PZQ will transit through the mesenteric veins where most of the adults S. mansoni worms are
located. To enhance the understanding of the PK/PD relationship, an opposite strategy can be
applied, by pre-treating the mice with dexamethasone (DEX), an inducer of several CYPs,
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before PZQ administration to try to decrease systemic plasma exposures. In this study, results
of the above mentioned in vivo strategies are disclosed and supported by in vitro parasitological
works.
Methods
In vivo study design and procedure
Ethics considerations. In vivo studies were conducted at the Swiss TPH, Basel, and
approved by the veterinary authorities of the Canton Basel-Stadt (permit no. 2070) based on
Swiss cantonal (Verordnung Veterina¨ramt Basel-Stadt) and national regulations (the Swiss
animal protection law (Tierschutzgesetz).
Blood sampling of healthy subjects for in vitro experiments conducted at helminGuard was
made upon informed written consent.
In vivo studies. Three-week old NMRI mice were purchased from Charles River (Sulzfeld,
Germany) and allowed to adapt under controlled conditions (temperature ca. 22˚C; humidity
ca. 50%; 12-hour light and dark cycle; free access to rodent diet and water) for one week.
Thereafter, they were infected subcutaneously with approximately 100 S. mansoni cercariae
(Liberian strain), harvested from infected intermediate host snails Biomphalaria glabrata by
exposure to light for 3 hours. Seven weeks post-infection, 6 mice were assigned to each PZQ
treatment group, while 8 mice were left untreated to serve as controls.
Commercially available PZQ, i.e. racemic PZQ, (Sigma-Aldrich) was administered to the
mice. For CYP inhibition studies, mice were pre-treated with i.v. or p.o. ABT (Sigma-Aldrich)
1 and 2 hours before p.o. administration of PZQ, respectively [15]. For CYP induction studies,
mice were pre-treated with DEX (Acros Organics) for 3 days, with once a day i.p. administra-
tion of 100 mg/kg prior to p.o. administration of PZQ [16]. From each treated mouse 4 blood
samples of 35 μL were collected from the tail vein at 0.5, 1.5, 2.5, 4 h post-dosing (0.5, 2.5, 4
and 7 h for groups treated with ABT). Five to 15 minutes after blood collection, samples were
centrifuged at 2500 g for 5 minutes at room temperature. Blood cells were discarded and the
obtained plasma (approximately 10–20 μL) was deep frozen and stored at –20˚C. Three weeks
post treatment mice were sacrificed by CO2 asphyxiation and dissected. The mesenteric tissue
and the liver were collected. Adult worms were removed from the hepatic portal system and
the mesenteric veins. The liver was flattened and examined for the presence of worms. Worms
in the liver and mesenteric veins were recorded. The worms were washed, sexed, and counted
using a binocular microscope. The worm burden (WB) of treated animals was calculated and
compared with the worm burden of control mice (n = 8), which have been infected simulta-
neously but have not been treated. The worm burden reduction (WBR) is calculated as follows:
WBR [%] = 100%—(100% / WBcontrol
 WBtreatment). The vehicle for p.o. application was 7%
Tween / 3% ethanol, for i.v. application 2% DMSO / 20% Hydroxypropyl-beta-cyclodextrin
and for i.p. administration was corn oil. Control mice were not treated.
Pharmacokinetic analyses
(R)-PZQ and (S)-PZQ levels were determined by LC-MS/MS at Merck using an enantioselec-
tive method (HPLC column: Lux 3μ Cellulose-2, 150 x 2 mm, Phenomenex. Solvents were
80% 20 mM ammonium hydrogen carbonate and 20% acetonitrile + 0.1% diethylamine. Flow:
200 μL/min. Retention times for (R)-Praziquantel is 630 min and (S)-Praziquantel is 824
min). Non-compartmental pharmacokinetic analysis was performed using PKsolver 2.0 [17].
For PZQ dose response studies, the fraction escaping hepatic metabolism, FH, was estimated
to be ~ 0.05 therefore we calculated the portal vein exposure as follows: Portal vein AUC0-t =
Systemic plasma AUC0-t / FH
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For CYP inhibition studies, we followed the hypothesis that ABT completely inhibited
hepatic CYP-mediated metabolism therefore the portal vein exposure was: Portal vein AUC0-t
= Systemic plasma AUC0-t
In vitro study design and procedure
In vitro culture of S. mansoni. S. mansoni cercariae (Liberian strain, University of Gies-
sen) were mechanically transformed using routine procedures. Schistosomula were cultured
following the protocol of Basch [18] (slightly modified) in Iscove’s modified Dulbecco’s
medium (PAA Laboratories GmbH) containing 5 μg/mL insulin (Gibco), 50 μg/mL transferrin
(Sigma Aldrich), 100 U/mL penicillin (PAA), and 100 μg/mL streptomycin (PAA) with 10%
foetal calf serum, FCS (PAA). After 24 h, human peripheral blood mononuclear cells (PBMC)
from healthy donors were added at a concentration of 8 × 102 cells per μL. After 48 h, human
serum (final concentration 20%) and whole blood (0.3%) were added to the culture system.
Culture was performed at humidified air at 37˚C and 6% CO2. Schistosomula developed into
adult stage including pairing after about 5–6 weeks.
Drug testing. For assessment of efficacy, DMSO solutions of (R)-PZQ, (S)-PZQ, PZQ
metabolites [6], ABT and DEX were added to adult worms at the concentrations indicated.
Testing was performed in 24-well plates (10–15 worms per well, duplicates). Following defined
time intervals, drugs added at various concentrations were largely removed from the culture
by 6 to 8 x replacing 50% of the medium by means of an automated microplate washer (BioTek
MultiFlo FX). Thereafter, 50% of medium/blood cells were replaced every 2–3 days. Worms
cultured in 0.1% DMSO served as negative control. Racemic PZQ and mefloquine (Selleck-
Chem) were used as positive controls. Evaluations were performed at 1.5 h, 24 h, and day 7.
Protein binding assay. PZQ protein binding was determined by Rapid Equilibrium Dial-
ysis [19]. The experimental fraction unbound (Fub) for (R)-PZQ in mouse plasma was ~20%
and for the in vitro assay ~50%. Fub was used to calculate the free area under the curve:
freeAUC = AUC  Fub.
Statistical method. Statistical comparisons were done using the Kruskal Wallis Test using
Statsdirect statistical software at a significance level of p< 0.05.
Results
In vivo pharmacokinetic and efficacy findings
WBRs and key pharmacokinetic exposure parameters are presented in Table 1. Without ABT
treatment, the 200 mg/kg PZQ dose resulted in a significant (68%) WBR when compared to
untreated control mice and the 400 mg/kg dose yielded a 97% WBR with a plasma Cmax of (R)-
PZQ of 6.3 μM and AUC0-t of 11.4 μMh [20]. With ABT treatment through the i.v. or the p.o.
route, mice dosed with a single oral dose of PZQ at 50 mg/kg, 100 mg/kg and 200 mg/kg pre-
sented an increase in the Cmax and AUC0-t of (R)-PZQ. Oral administration of ABT provided a
greater increase in exposure than i.v. administration for the 50 and 100 mg/kg PZQ doses. 50
mg/kg of PZQ p.o. with 50 mg/kg ABT i.v. achieved similar Cmax, and AUC0-t to the positive
control while the WBR was only 21%. Moreover, 100 mg/kg of PZQ p.o. with 20 mg/kg ABT i.
v. showed ~2 times greater Cmax, and ~3 times greater AUC0-t versus the positive control but
only achieved a WBR of 60%. Finally treating the mice with ABT i.v. or p.o. before administer-
ing a 200 mg/kg dose of PZQ led to an improved WBR: 100% and 88%, after ABT i.v. and p.o.,
respectively, vs. 68% without ABT. However to achieve such efficacy a Cmax increase by ~5
fold and an AUC0-t increase by ~10 fold of the positive control was required.
In a second study, a 400 mg/kg oral dose of PZQ provided a median WBR of 84%. When
PZQ was given at the same dose to mice pre-treated with the CYP inducer DEX, a similar
PK-PD relationship of praziquantel in the Schistosoma mansoni mouse model
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median WBR of 73% was obtained with a ~10 fold decrease in exposure of (R)-PZQ in com-
parison to the positive control (Table 2).
Analysis of PK/PD relationship
Fig 1 depicts the plotting of individual mouse data for total plasma Cmax, AUC0-t and dose as a
function of WBR. In the absence of ABT, systemic plasma exposure (Cmax and AUC0-t) does
not correlate with the WBR but appears to correlate linearly with the dose. In the presence of
ABT, a non-linear correlation could be observed between the AUC0-t and the WBR.
In mice, estimation of the portal vein exposures in the groups not treated with ABT was
made by assuming that 95% of PZQ was cleared after first pass in the liver (FH = 0.05), and
that the PK was dose linear. The assumption for FH was based on the comparison of PK pro-
files between the 200 mg/kg dose with and without ABT i.v, where after i.v. administration of
ABTthe hepatic metabolism of PZQ was considered to be completely inhibited. For the groups
























b) 6.3 (3.6–21.0) 11.4 (6.5–25.7) 97 (84–100) 6 p<0.05
200 - b) 4.2 (0.5–9.9) 7.1 (1.2–11.1) 68 (65–71) 6 p<0.05
200 20; i.v. 34.6 (33.3–48.0) 113.5 (84.3–200.0) 100 (97–100) 5 p<0.05
200 50; p.o. 35.7 (20.5–38.7) 127.6 (34.6–163.8) 88 (54–100) 4 p<0.05
100 20; i.v. 13.4 (6.9–33.9) 31.2 (8.4–117.9) 60 (12–73) 5 p<0.05
100 50; p.o. 24.3 (11.5–40.3) 53.2 (25.2–112.3) 79 (54–95) 5 p<0.05
50 50; i.v. 9.5 (8.2–10.8) 14.2 (13.7–14.8) 21 (14–28) 2d) -
50 50; p.o. 11.8 (10.3–19.9) 22.3 (10.0–39.2) 53 (0–71) 6 p<0.05
a) Untreated NMRI mice inoculated with ~100 S. mansoni cercariae harbored a mean of 37.3 ± 88 worms with 95% of them located in the mesenteric veins;
b) No ABT was administered;
c) Several mice died from the severity of the infection;
d) ABT i.v. at 50 mg/kg was not well tolerated and was replaced by 20 mg/kg in other groups.
e) Statistical comparisons were done using the Kruskal Wallis Test at a significance level of p < 0.05
https://doi.org/10.1371/journal.pntd.0005942.t001
























b) 11.7 (8.5–16.3) 120 (9.8–17.2) 84 (38–92) 4 p<0.05
400 100; i.p. 1.2 (0.2–1.8) 12 (0.2–1.7) 73 (46–100) 4 p<0.05
a) Untreated NMRI control mice inoculated with ~100 S. mansoni cercariae harbored a mean of 12.9 ± 6.3 worms with 95% of them located in the
mesenteric veins;
b) No DEX was administered.
c) Statistical comparisons were done using the Kruskal Wallis Test at a significance level of p < 0.05
https://doi.org/10.1371/journal.pntd.0005942.t002
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treated with ABT, we assumed that i.v. and p.o. ABT completely inhibited hepatic CYP-medi-
ated metabolism. Therefore the portal vein total exposure is equivalent to the systemic plasma
exposure. As seen in Table 3, the values obtained from the group not treated with ABT were in
agreement with the corresponding experimental values using ABT p.o. and i.v.
The (R)-PZQ extrapolated portal vein exposures for treated mice were plotted against
WBR. This correlation suggests that a portal vein AUC0-t of (R)-PZQ greater than ~100 μMh
needs to be reached in order to achieve a WBR greater than 60%. (Fig 2). The corresponding
free portal vein exposure (freeAUC0-t) responsible for the activity was found to be ~20 μMh as
(R)-PZQ is ~20% unbound in mouse plasma.
In vitro studies
Table 4 displays the activity of (R)-PZQ, (S)-PZQ, PZQ metabolites [6], ABT and DEX on
adult S. mansoni in an enhanced in vitro assay.
Positive controls were PZQ & mefloquine, which, incubated at 10 μM for 24 h, resulted in
severe degeneration, death or no motility of the worms whereas as DSMO had no effect on
worms. At 2.1 μM for 24 h (AUC = 50 μMh; freeAUC = 25 μMh; Fub ~50%), (R)-PZQ led to
Fig 1. Correlation plots. Panel (A): %WBR vs. Cmax; Panel (B): %WBR vs. AUC0-t; Panel (C): %WBR vs. dose. Individual data
points. In blue experiments without ABT; in red experiments with ABT.
https://doi.org/10.1371/journal.pntd.0005942.g001





median (range) without ABT
a)
(R)-PZQ AUC0-t (μM*h),
median (range) with ABT i.v.
b)
(R)-PZQ AUC0-t (μM*h),
median (range) with ABT p.
o. b)
50 27.5 (14.8–53.2) 14.2 (13.6–14.8) 22.3 (10.0–39.2)
100 39.5 (24.9–76.8) 31.2 (8.4–117.9) 53.2 (25.1–112.3)
200 142.1 (23.7–222.0) 113.5 (84.3–200.0) 127.6 (34.6–163.8)
400 227.1 (129.0–513.1) - -
a) Portal vein AUC0-t = Systemic plasma AUC0-t / FH; FH is the fraction escaping hepatic metabolism and is
estimated to be at 0.05.
b) Assuming ABT completely inhibited hepatic CYP-mediated metabolism, Portal vein AUC0-t = Systemic
plasma AUC0-t
https://doi.org/10.1371/journal.pntd.0005942.t003
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shrinkage and paralysis of the worms with persisting damages at day 7. At a similar concentra-
tion (S)-PZQ the worms became only transiently hyperactive.
When incubating all major previously disclosed metabolites formed, i.e. cis- and trans
4-hydroxy-PZQ of each enantiomer, at the very high concentration of 50 μM for 24 h
(AUC = 1200 μMh), only the (R)-PZQ derived metabolites revealed significant short term
effects although worms could almost fully recover from it at day 7.
Finally, incubating ABT or DEX at 10 μM for 24 h had no effect on adult S. mansoni.
Fig 2. The correlation between efficacy expressed as worm burden reduction in % (y axis) and
extrapolated AUC0-t in the portal vein expressed in μM*h (x axis). Individual data points. In blue
experiments without ABT; in red experiments with ABT.
https://doi.org/10.1371/journal.pntd.0005942.g002
Table 4. In vitro effects of (R)-PZQ, (S)-PZQ, PZQ metabolites [6], ABT and DEX against adult S. mansoni.
Compound Conc Incubation Time SchistoToxa), b) at 1.5 h SchistoTox at 24 h SchistoTox at 7 day
(R)-PZQ 2.1 μM 24 h 2 2 1.5
(S)-PZQ 2.1 μM 24 h 0 0 0
Cis-4-hydroxy-(R)-PZQ 50.0 μM 24 h ND 1.5 0.7
Trans-4-hydroxy-(R)-PZQ 50.0 μM 24 h ND 1.5 0
Cis-4-hydroxy-(S)-PZQ 50.0 μM 24 h ND 0 0
Trans-4-hydroxy-(S)-PZQ 50.0 μM 24 h ND 0 0
ABT 10 μM 24 h 0 0 0
Dexamethasone 10 μM 24 h 0 0 0
DMSO 0.1% 24 h 0 0 0
PZQ 10 μM 24 h 2 2 2
Mefloquine 10 μM 24 h 0 1.9 2
a) SchistoTox scale indicates the degree of damage of adult S. mansoni worms at day 7 post exposure from 0 (healthy worms) to 2 (severe degeneration,
death or no motility of the worms);
b) 10–15 adult S. mansoni per well (24 well plate, n = 2)
https://doi.org/10.1371/journal.pntd.0005942.t004
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Discussion
In the S. mansoni mouse model our study showed that a single dose of PZQ at 400 mg/kg was
required to achieve excellent efficacy i.e. a WBR greater than 85% as compared to the control
group in good agreement with previous work [21]. The very high metabolism of PZQ in the
mouse [22] hampers achieving good systemic exposures with lower single, oral doses and we
therefore hypothesized that pre-administration of a non-specific irreversible inhibitor of CYP
such as ABT could reduce the clearance in mice and therefore increase PZQ concentrations
and exposures (i.e. Cmax, AUC) in the plasma. The aim was to determine whether efficacy at
doses lower than 400 mg/kg could be increased by increasing the plasma exposures for the
same doses of PZQ. As expected, plasma exposures in the systemic circulation of the active
enantiomer (R)-PZQ were increased by ~10 to ~20 fold when ABT was pre-administered.
However, it appeared that ABT had limited impact on the efficacy: 50 mg/kg PZQ in mice pre-
treated with ABT allowed reaching similar plasma exposures of (R)-PZQ to mice dosed with
400 mg/kg without any ABT pre-treatment, but the efficacy was lower (Table 1). The higher
WBRs observed when ABT was administered p.o. over i.v. for 50 and 100 mg/kg PZQ doses
suggest a role of intestinal metabolism, which is inhibited by oral ABT administration. ABT
had limited impact on the t1/2 which ranged between 0.4–3 h after p.o. administration (Data
available on request), in the presence and absence of ABT; however accurate assessment of the
terminal phase was not possible due to the limited number of time points following the Cmax.
Our data suggest that the systemic plasma exposure of PZQ is neither predictive nor the main
contributor to the efficacy in the S. mansoni mouse model. This was strikingly demonstrated
when administering the CYP inducer DEX prior to treatment with 400 mg/kg PZQ (Table 2).
A similar level of efficacy was achieved with the same dose of PZQ, as compared to the positive
control, while plasma exposures were decreased by ~10 fold.
It is therefore likely that high local concentrations of (R)-PZQ in the mesenteric veins, the
target organ for adult S. mansoni, are required to achieve good efficacy, and that systemic
exposures do not play a key role in the efficacy. The latter has been suggested by Xiao et al. in
rabbits infected with S. japonicum; however, in this study, no correlation was observed with
portal vein concentrations either [23].
Extrapolation of exposures in the portal vein, and thus in mesenteric veins, in mice led to
the conclusion that ~100 μMh (freeAUC ~20 μMh) was needed to reach significant worm
burden reduction i.e. greater than 60%. Additional in vitro experiments showed that a freeAUC
of (R)-PZQ of 25 μMh produced long lasting damages to the worms, whereas the opposite
enantiomer, (S)-PZQ, had only transient effects. Additionally, we have shown that 4-hydroxy-
(R)-PZQ metabolites, formed at high concentration during first pass metabolism, affected only
the worm viability on short term but are unlikely to be the main drivers for the efficacy. This is
in agreement with previously published data [6]. An obvious caveat is that the in vitro assay
cannot fully mimic the immune system of a living organism, a main contributor of the efficacy
of PZQ [1, 2].
Regarding the relevance of these data in humans, like with any pharmacological model per-
formed in preclinical species, the translation of mouse data to the human situation has to be
done with caution. For example, the clearance is greater in the mouse and the contribution of
the immune response may differ between species. However, the location of the parasite is the
same in the mouse model and in human patients, and hepatic metabolism pathways are similar
between both species [14]. Therefore, we believe that the major conclusion from this study, i.e.
concentrations in the mesenteric/portal vein before first-pass hepatic metabolism are driving
the efficacy in mice, could also be applicable to humans. As a consequence, we propose that
PZQ efficacy in S. mansoni infections might be guided by the total administered PZQ dose.
PK-PD relationship of praziquantel in the Schistosoma mansoni mouse model
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PZQ is highly permeable but has limited solubility therefore undergoes slow absorption from
the gut lumen (BCS class II) [24]. Assuming similar absorption of PZQ is reached across age
groups, low weight patients could then present a risk of reaching lower absolute concentra-
tions of PZQ in the target veins and may provide an explanation for the observed reduced effi-
cacy in some recent pediatric clinical trials [11,12].
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